Amarin Corp Plc (AMRN)

[sts66]

How about this gem? Many drugs, perhaps > 50%, do not have a fully understood MOA - that's not a valid reason to say "we shouldn't cover this drug" - and furthermore, not fully knowing MOA does NOT invalidate the empirical results of a 7 yr CVOT - the only thing that matters is "did it work or not?" - and CLEARLY it worked wonderfully. This attitude shows a very poor understanding of how medical treatments are guided by clinical trial results, NOT by "what is going on inside the body that produced the desired outcome?". I mean NOBODY has a frigging clue how anti-depressants work - does the UK cover them given their unknown MOA? Of course they do.

3.7 The company stated that icosapent ethyl’s mechanism of action is not fully understood. The company noted it appears to modulate the atherosclerosis pathway by lipid and non-lipid effects. It explained the primary lipid effect is reducing triglyceride levels. It added that the non-lipid effects may include localised anti-inflammatory effects, regulation of lipid metabolism gene transcription, antithrombotic effects and plaque reduction. The clinical experts also commented that the mechanism action is uncertain. They explained that the reduction in cardiovascular risk observed in REDUCE-IT was larger than what would be expected from a reduction in triglycerides alone. The committee concluded that the mechanism of action is not fully understood, which adds uncertainty to the trial’s results.